SOAT1 and acute lymphoblastic leukemia: Ruxolitinib inhibits the JAK/STAT signaling pathway, blocking aberrant proliferation and survival signals induced by CRLF2 rearrangement. This overcomes the TSLPRCART resistance in ALL PDXs